The inception of cancer treatment with chemotherapeutics began in the 1940s with nitrogen
mustards that were initially employed as weapons in World War II. Since then, treatment …

Esophageal cancer (EC) is a common gastrointestinal malignancy with poor prognosis and
high mortality. Although combined therapeutic strategies have been developed, the 5-year …

Radiopharmaceuticals play a vital role in cancer therapy. The carrier of
radiopharmaceuticals can precisely locate and guide radionuclides to the target, where …

Therapeutic radiopharmaceuticals have been researched extensively in the last decade as
a result of the growing research interest in personalized medicine to improve diagnostic …

The present article highlights the important progress made in the last two decades in the
fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based …

CD20 located predominantly on the B cells plays a crucial role in their development,
differentiation, and activation, and serves as a key therapeutic target for the treatment of B …

Radioimmunotherapy (RIT) is FDA-approved for the clinical management of liquid
malignancies, however, its use for solid malignancies remains a challenge. The putative …

For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20–based
immunochemotherapy or develop relapsed or refractory disease, there remains a significant …

Immunotherapies that target the CD20 protein expressed on most non-Hodgkin lymphoma
cells have improved clinical outcomes, but relapse is common. We prepared 225Ac-labeled …

Monoclonal antibodies (mAbs) are a group of antibodies produced by identical clones of B
lymphocytes against a particular antigen. mAbs are identical in several properties such as …